印度代购温馨提示，黑色素瘤靶向治疗药物-考比替尼：考比替尼（卡比替尼）于2015年获美国FDA批准上市，与维莫非尼联合使用用于治疗BRAF V600E或 V600K变异的晚期黑色素瘤。BRAF可以让黑色素瘤细胞增长，所有类型黑色素瘤中大约有一半会发生这种基因突变，这也是药物的作用靶点。考比替尼（卡比替尼）治疗黑色素瘤是典型的下游截流机理，通过抑制MEK的活性阻断由于KRAS或BRAF突变引发的通路异常，阻止或减慢癌细胞生长。

Corbitinib: Corbitinib (Carbitinib) was approved by FDA in 2015 for the treatment of advanced melanoma with BRAF V600E or V600K mutation in combination with Vimofinib. BRAF allows melanoma cells to grow, a mutation that occurs in about half of all types of melanoma and is a target of the drug. Cobitinib (carbitinib) is a typical downstream closure mechanism for melanoma, blocking pathway abnormalities due to KRAS or BRAF mutations by inhibiting MEK activity and preventing or slowing cancer cell growth.

　　印度代购温馨提示考比替尼的临床应用：

　　（1）黑色素瘤

　　威罗非尼联合考比替尼治疗BRAF突变的晚期黑色素瘤患者，无进展生存期PFS为12.3个月，比威罗非尼单药组（PFS7.2月）延长5个月！

　　（2）结直肠癌

　　PDL1单抗阿特朱单抗联合考比替尼治疗KRAS突变的结直肠癌患者，有效率ORR是20%。

　　试验中也包含微卫星稳定MSS的结直肠癌患者，此类患者单用免疫治疗的疗效一般，但联合考比替尼后可以改善免疫微环境来提高MSS患者的整体免疫疗效。

The trial also included microsatellite-stabilized MSS in colorectal cancer patients, who had moderate response to immunotherapy alone, but who were able to improve the immune microenvironment in combination with corbitinib to improve overall immune response in MSS patients.